Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu
© Borgis - Postępy Nauk Medycznych 12/2015, s. 852-857
*Jarosław Kozakowski
Interwencyjne leczenie cukrzycy typu 2
Interventional treatment for type 2 diabetes
Department of Endocrinology, Centre of Postgraduate Medical Education, Bielański Hospital, Warszawa
Head of Department: prof. Wojciech Zgliczyński, MD, PhD
Otyłość i cukrzyca typu 2 należą obecnie do najpoważniejszych problemów zdrowotnych w krajach rozwiniętych i rozwijających się. Według standardów leczenia cukrzycy, zwłaszcza z towarzyszącą otyłością, redukcja masy ciała stanowi zasadniczy element terapii. Jednak uzyskanie spadku wagi i jego utrzymanie jest często bardzo trudne. Wynika to z ograniczonej efektywności stosowanych metod oraz z niechęci pacjentów do utrzymywania rygorów dietetycznych i aktywności fizycznej. Z drugiej strony, od dawna już wiadomo, że skutecznym sposobem osiągnięcia istotnej redukcji masy ciała jest operacja bariatryczna. Obecnie na świecie przeprowadzono już kilka milionów takich zabiegów. Od czasu wprowadzenia techniki laparoskopowej są one coraz bardziej bezpieczne, skuteczne, a wielość typów operacji pozwala na dostosowanie odpowiedniej metody indywidualnie do każdego pacjenta.
Praca krótko przedstawia różne rodzaje operacji, zasady kwalifikowania i przygotowywania pacjentów do zabiegu, a także najważniejsze problemy, o których lekarz internista powinien pamiętać, prowadząc pacjenta po operacji. Wspomniane są także alternatywne do operacji, mniej inwazyjne metody interwencyjnego leczenia cukrzycy i otyłości.
Obesity and type 2 diabetes are currently the most serious health problems in developed and developing countries. According to standards of treatment of diabetes, especially with obesity, weight reduction is an essential element of therapy. However, to obtain a decrease in weight and its maintenance is often very difficult. This is due to the limited effectiveness of the available methods and to the reluctance of patients to maintain the rigors of dietary and physical activity. On the other hand, it is quite well known already that bariatric surgery is an effective way to achieve a significant reduction in body weight. Now several million such surgical interventions has already been carried out all over the world. Since the introduction of the laparoscopic technique, they are getting more safe, effective, and the variety of types of operation allows to adjust the appropriate method individually for each patient.
Review briefly presents the different types of operations, the rules for eligibility and preparing patients for surgery, as well as the most important problems which the physician should remember in care about the patient after surgery. These are also an alternative to surgery, less invasive methods of intervention treatment of diabetes and obesity described.

Obesity is the most common metabolic disease nowadays. According to the World Health Organization (WHO) it is now reaching an epidemic size, and is the biggest health problem in developed and developing countries. WHO estimates that in 2008 there were 200 million of obese men and 300 million obese women all over the world, and 2-3 times as many were overweight. At the end of 2009 more than 45% men in Poland were overweight and 17% of them were obese (1). Among women the figures reached 30 and 15% respectively (2). Obesity, especially abdominal one, is known to contribute to the development of many metabolic disorders and diseases, including type 2 diabetes. About half of diabetics are thought to be obese (3). Nearly 350 million people are suffering from diabetes currently. In Poland, as is evidenced by NATPOL (III) research, 6-8% of the adult population are affected (4).
Standard procedures, regularly updated by the diabetics associations, invariably involve primarily the modification of lifestyle, and secondly a pharmacological treatment using one (metformin) or more drugs, including insulin (5, 6). Although weight reduction is an essential element of the therapy, experience shows that it is often difficult to obtain. This results on the one hand from a limited effectiveness of the methods and on the other one from the patients reluctance to maintain the rigorous diet and physical activity, especially long-term ones. This is why less than half the patients obtain the therapeutic aims (7).
An effective method of significant weight reduction, known for dozens of year, is bariatric surgery. The first attempts of jejunum-to-ileum or colon anastomosis and DeWind and Payne’s intestinal exemption treatment were made in 1950-60. In 1971 the first gastroplasty was performed, while the years 1970-80 brought on a vertical division of the upper part of the stomach and securing the channel along the lesser curvature with grid (vertical banded gastroplasty – VBG) or drain (silastic ring vertical gastroplasty – SRVG). The 1980s were marked of adjustable clamps. In the next years the operating techniques were developed and modified until the ones known now. A real breakthrough was the introduction of laparoscopic technique in the 1990s; it is now widely used in bariatric surgery (8-10).
For about 20 years the beneficial metabolic effects of body mass surgery have been highlighted (11). Currently there is abundant evidence that this treatment causes a rapid, substantial and long-lasting improvement in glycemic control in patients with type 2 diabetes (12-14). For this reason the term of metabolic surgery has come into use, although the concept was already considered at the end of 1970s. Metabolic surgery is defined as a surgical technique that modifies the digestive tract so that the change in the passage of food results in improving glycemic control in diabetes as a result of launching some mechanisms independent of weight reduction. Thus, the first purpose of metabolic surgery is not a weight reduction, but metabolic improvement.
A high effectiveness combined with lower perioperative complications risk resulted in a rapid growth in the number of operations performed worldwide. In 2013 179,000 such procedures were performed in the US (15). In the years 1993-2006 in Poland 2,584 such operations were made (16), and currently about 1,500 are performed annually. Current indications for the procedure, as defined in the recommendations by the Polish Association for the Study of Obesity, include severe obesity (BMI ≥ 40 kg/m2) or II° obesity (BMI = 35 to 39.9 kg/m2) with associated diseases, whose course can improve following a surgery, such as type 2 diabetes and other metabolic disorders, cardiovascular diseases, respiratory, bone and joint problems as well as severe psychological problems among people aged 18 to 60 (17). Similar criteria have been determined by other scientific societies, e.g. European Society for Endoscopic Surgery (EAES), the American Gastroenterological Association (AGA) or the American Society of Cardiology (AHA). Recently International Diabetes Federation (IDF) recommends considering an operation also for people with BMI 30-35 kg2 with poorly controlled type 2 diabetes despite optimal pharmacological treatment, especially with an increased cardiovascular risk. Contraindications for the surgery include lack of earlier attempts at conservative treatment, inability to observe recovery, not stabilized mental illness and emotional disorders, alcoholism, drug addiction, lack of support from family or caregivers.
The bariatric operations currently performed can be divided into restrictive, i.e. those which limit the amount of food consumed, or reducing absorption (exempting, malabsorption) or restrictive-excluding, so those which combine the two previous techniques. The first are technically easier to perform, shorter and less aggravating for the patient. Exempting treatment results in a greater loss of body weight and is more effective, though it increases the risk of malnutrition. There are many surgical methods, which, as has been mentioned before, are constantly refined and developed, but in practice the most common ones include:
– laparoscopic adjustable gastric binding (LAGB),
– sleeve gastrectomy (SG),
– Roux-an-Y Gastric Bypass (RYGB).
A modification of the last one, which disconnects a larger section of the digestive tract, is the co-called Scopinaro procedure, i.e. BPD: bilio-pancreatic diversion or its variant, BPD-DS: bilio-pancreatic diversion-duodenal switch.
Adjustable gastric band is a very common procedure (46% of all bariatric surgeries in 2010) (18), due to positive results with a favorable safety profile, as demonstrated in many studies. Perioperative mortality for this method is < 0.1% within 30 days (19). The treatment is fully reversible and causes low nutritional deficits. For these reasons in 2011 American food and Drug Agency (FDA) allowed its application for patients with BMI of 30-35 kg/m2, who also suffer from obesity-dependent diseases. Disadvantages of this method include the need of strict dietary control, possible vomiting, a possibility that the clamp can move or grow into the wall of the stomach. Less than 25% of the patients maintain good results after 14 years of observation, and 68% require repetition of surgery.
The most frequently performed operation in the world today is sleeve gastrectomy. In 2013, this surgery accounted for 42% of all bariatric surgeries in the United States (15). It involves removing a vast majority of the stomach and leaving only a small part along the lesser curvature. The advantages of such operations include a significant reduction in the capacity of the stomach and the removal of the ghrelin-producing part with a subsequent significant decline in its concentration and a growing concentration of YY (PYY) peptide. The disadvantage is a long anastomosis line and a possibility of a leak.
Another frequently performed procedure, although much more invasive, is Roux-en-Y gastric bypass. While the two previous techniques might be considered restrictive, RYGB is a mixed type, and as such it limits absorption. In 2013 it accounted for 34% of all bariatric surgeries carried out in the United States (15). The procedure consists in transecting with staplers a part of cardia area of approx. 20 ml capacity, which is then connected by anostomosis with a selected loop of the small intestine. This excludes the remaining part of the stomach, duodenum and the initial 60-100-cm section of the jejunum. The proximal end of the small intestine, formed after the resection, is connected end-to-side with a further intestinal loop, just about 100 cm from the stomach body and it is only at this point that the food mixes with pancreas enzymes and bile, which enables efficient digestion and absorption. The advantages of this method are: a significant reduction in the amount of food received and reversibility. The disadvantages include possible band breaking, blockade between the intestines and stomach, the need to comply with a diet and vitamin supplementation for the rest of patient’s life. RYGB can be considered the “gold standard” of the bariatric surgeries. For over 40% patients operated in this way remission of diabetes was reported and 69% do not use medication even after 3 years of the procedure (for the sleeve gastrectomy the figure was 43%). Complications associated with Roux-en-Y are about 4-5%, the mortality rate is 0.2%, and embolism (pulmonary and venous) 0.4%. Only 3-5% of the patients require reoperation.
Generally it is believed that, regardless of type, such operations should be performed by experienced surgeons in the centers evaluated by independent monitoring organizations. Clinical studies indicate that bariatric treatment in patients with type 2 diabetes lead to a significant reduction in body weight, and considerably improve glycemic control and metabolic rates.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. Tsigos C, Hainer V, Basdevant A et al.; Obesity Management Task Force of the European Association for the Study of Obesity: Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1(2): 106-116.
2. Główny Urząd Statystyczny: Stan zdrowia ludności Polski w 2009 roku. Warszawa 2011.
3. Leibson CL, Williamson DF, Melton LJ III et al.: Temporal trends in BMI among adults with Diabetes. Diabetes Care 2001; 24(9): 1584-1589.
4. Zdrojewski T, Bandosz P, Szpakowski P et al.: Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo-naczyniowego w Polsce. Wyniki badani NATPOL PLUS. Kardiol Pol 2004; 61(suppl. IV): 15-17.
5. American Diabetes Association: Standards of medical care in diabetes 2015. Diabetes Care 2015; 38 (suppl. 1): S1-S9.
6. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2015. Diabetologia kliniczna 2015; 4 (suppl. A): 2299-2529.
7. Ali MK, Bullard KM, Saaddine JB et al.: Achievement of goals in U. S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-1624.
8. Payne JH, DeWind LT: Surgical treatment of obesity. Am J Surg 1969; 118: 141-147.
9. Kuzmak LI: A Review of Seven Years’ Experience with Silicone Gastric Banding. Obes Surg 1991; 1(4): 403-408.
10. Favretti F, Cadiere GB, Segato G et al.: Laparoscopic Adjustable Silicone Gastric Banding: Technique and Results. Obes Surg 1995; 5(4): 364-371.
11. Pories WJ, Swanson MS, MacDonald KG et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995 Sep; 222(3): 339-352.
12. Buchwald H, Estok R, Fahrbach K et al.: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256.
13. Puzziferri N, Roshek TB 3rd, Mayo HG et al.: Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312: 934-942.
14. Mingrone G, Panunzi S, De Gaetano A et al.: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366(17): 1577-1585.
15. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers.
16. Stanowski E, Wyleżoł M, Paśnik K: Laparoskopia w chirurgii bariatrycznej w Polsce – stan aktualny. Wideochirurgia i inne techniki małoinwazyjne 2007; 2(1): 18-23.
17. Tsigos C, Hainer V, Basdevant A et al. for the Obesity Management Task Force of the European Association for the Study of Obesity: Management of obesity in adults: European clinical practice guidelines. Endocrionology, Obesity and Metabolic Disorders 2009; 5(3): 87-98.
18. Hutter MM, Schirmer BD, Jones DB et al.: First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 2011; 254(3): 410-420.
19. Ding SA, Simonson DC, Wewalka M et al.: Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial. J Clin Endocrinol Metab 2015; 100(7): 2546-2556.
20. Gloy VL, Briel M, Bhatt DL et al.: Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013 Oct 22; 347: f5934. doi: 10.1136/bmj.f5934.
21. Shimizu H, Timratana P, Schauer PR, Rogula T: Review of Metabolic Surgery for Type 2 Diabetes in Patients with a BMI < 35 kg/m2. J Obes 2012; 147256. doi: 10.1155/2012/147256.
22. Lee WJ, Chong K, Chen CY et al.: Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35 kg/m2. Obes Surg 2011; 21(7): 889-895.
23. Scopinaro N, Adami GF, Papadia FS et al.: Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011; 253(4): 699-703.
24. Knop FK: Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009; 52(11): 2270-2276.
25. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335-342.
26. Heneghan HM, Meron-Eldar S, Brethauer SA et al.: Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol 2011; 108(10): 1499-1507.
27. Sjöström L, Narbro K, Sjöström CD et al.; Swedish Obese Subjects Study: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357(8): 741-752.
28. Lebovitz HE, Ludvik B, Kozakowski J et al.: Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial. Physiol Rep 2015; 3(7). pii: e12456. doi: 10.14814/phy2.12456.
otrzymano: 2015-10-30
zaakceptowano do druku: 2015-11-23

Adres do korespondencji:
*Jarosław Kozakowski
Department of Endocrinology Centre of Postgraduate Medical Education Bielański Hospital
ul. Cegłowska 80, 01-809 Warszawa
tel. +48 (22) 834-31-31

Postępy Nauk Medycznych 12/2015
Strona internetowa czasopisma Postępy Nauk Medycznych